COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00083135
Recruitment Status : Completed
First Posted : May 17, 2004
Last Update Posted : October 15, 2010
National Cancer Institute (NCI)
Information provided by:
Children's Hospital Los Angeles

Brief Summary:

RATIONALE: Giving iodine I 131 metaiodobenzylguanidine (^131I-MIBG) may kill neuroblastoma cells by delivering radiation directly to the tumor. A stem cell transplant using the patient's stem cells may be able to replace blood-forming cells destroyed by radiation therapy.

PURPOSE: This phase I trial is studying the side effects and best dose of a double infusion of ^131I-MIBG followed by autologous stem cell transplantation in treating patients with refractory neuroblastoma.

Condition or disease Intervention/treatment Phase
Neuroblastoma Biological: filgrastim Procedure: autologous bone marrow transplantation Procedure: peripheral blood stem cell transplantation Radiation: iobenguane I 131 Phase 1

Detailed Description:



  • Determine the maximum tolerated red marrow radiation dose delivered and associated toxic effects of escalating activity of iodine I 131 metaiodobenzylguanidine (^131I-MIBG) followed by autologous hematopoietic stem cell transplantation in patients with refractory neuroblastoma.
  • Determine the number of days after stem cell transplantation to achieve absolute neutrophil count ≥ 500/mm^3 for 3 days and platelet count ≥ 20,000/mm^3 for 3 days (without transfusions) in patients treated with this regimen.


  • Determine the response rate in patients treated with this regimen, based on lesions measurable by CT or MRI at study entry, patients with ^131I-MIBG scan-positive lesions only, and patients with minimal residual tumor in bone marrow who have complete response by immunocytology and morphology.
  • Determine the tumor absorbed radiation dose in patients with measurable soft tissue lesions treated with this regimen.
  • Correlate, if possible, TP53 mutations with response in patients with accessible bone marrow tumor treated with ^131I-MIBG.

OUTLINE: This is a dose-escalation, multicenter study.

  • Iodine I 131 metaiodobenzylguanidine (131I-MIBG) therapy: Patients receive^131I-MIBG IV over 2 hours on days 0 and 14.

Cohorts of 3-6 patients receive escalating doses of ^131I-MIBG until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

  • Stem cell transplantation therapy: Patients undergo autologous peripheral blood stem cell transplantation on day 28. Patients receive filgrastim (G-CSF) IV over 1 hour OR subcutaneously daily beginning on day 28 and continuing until blood counts recover.

Patients are followed every 3 months for 1 year and then annually thereafter.

PROJECTED ACCRUAL: A total of 9-18 patients will be accrued for this study within 2 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Primary Purpose: Treatment
Official Title: I-MIBG Escalating Dose Rapid Sequence Double Infusion Followed By Autologous Stem Cell Infusion For Refractory Neuroblastoma
Study Start Date : March 2004
Actual Primary Completion Date : February 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Neuroblastoma

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   1 Year to 30 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of neuroblastoma

    • Confirmed by at least 1 of the following methods:

      • Histology
      • Clumps of tumor cells in bone marrow with elevated urinary catecholamine metabolites
    • High-risk disease

      • Poor response to induction therapy OR relapse defined by any of the following:

        • No response, stable disease, or mixed response after a minimum of 3 prior courses of chemotherapy
        • More than 100 tumor cells per 10^5 nucleated cells on bone marrow immunocytology after at least 3 prior courses of chemotherapy
        • Progressive disease at any time during or after therapy
        • Patients with massive bone marrow invasion (more than 50% replacement of bone marrow by tumor cells) are allowed
  • Must have positive iodine I 131 metaiodobenzylguanidine (^131I-MIBG) within the past 6 weeks or subsequent to any other prior antitumor therapy delivered within the past 6 weeks
  • Must meet the following criteria for minimum number of autologous stem cells:

    • Unpurged peripheral blood stem cells (PBSC)

      • Minimum of 1,500,000/mm^3 CD34-positive cells/kg
      • Collected products must have < 1 tumor cell/100,000 normal cells by immunocytology
    • PBSC purged with immunomagnetic beads

      • Minimum of 1,000,000/mm^3 viable CD34-positive cells/kg
      • Collected products must have < 1 tumor cell/100,000 normal cells by immunocytology
    • CD34-positive selected PBSC products are not allowed
    • Patients who had PBSC collected previously with no immunocytological testing available may use those products provided bone marrow is tumor free by bilateral bone marrow aspirate AND biopsy for morphology is performed within 4 weeks before PBSC collection
    • Patients with no tumor involvement in bone marrow at diagnosis and PBSC collection before any disease progression do not require documentation of negative bone marrow morphology



  • 1 to 30

Performance status

  • ECOG 0-2

Life expectancy

  • Less than 1 year


  • Absolute neutrophil count ≥ 500/mm^3
  • Platelet count ≥ 50,000/mm^3 (without transfusion)
  • Hemoglobin ≥ 8 g/dL (transfusion allowed)


  • AST and ALT ≤ 5 times normal
  • Bilirubin < 2 times normal


  • Creatinine ≤ 1.5 mg/dL
  • Glomerular filtration rate OR 12-hour creatinine clearance ≥ 60 mL/min/1.73m^2


  • Ejection fraction ≥ 55% by echocardiogram or MUGA OR
  • Fractional shortening ≥ 30% OR above lower limit of normal by echocardiogram


  • Normal lung function
  • No dyspnea at rest
  • No exercise intolerance
  • No oxygen requirement


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Able to cooperate physically and psychologically with radiation isolation
  • No disease of any major organ system that would preclude study participation
  • No active infection requiring antivirals, antibiotics, or antifungals
  • No weight that would require exceeding a maximum total allowable dose of ^131I-MIBG


Biologic therapy

  • At least 2 weeks since prior biologic or other non-myelosuppressive therapy


  • See Disease Characteristics
  • At least 2 weeks since prior chemotherapy
  • More than 3 months since prior myeloablative therapy

Endocrine therapy

  • Not specified


  • See Disease Characteristics
  • At least 6 months since prior craniospinal, total abdominal, or whole lung radiotherapy
  • At least 2 weeks since prior radiotherapy to any site
  • No prior total body irradiation
  • No prior radiotherapy to > 25% of bone marrow
  • No prior ^131I-MIBG


  • Not specified


  • Recovered from all prior therapy
  • Concurrent antifungal therapy allowed provided culture and biopsy are negative in suspected radiographic lesions
  • Prior re-induction therapy for recurrent tumor allowed
  • No concurrent antiretroviral therapy for HIV-positive patients
  • No concurrent hemodialysis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00083135

Layout table for location information
United States, California
Children's Hospital Los Angeles
Los Angeles, California, United States, 90027-0700
UCSF Comprehensive Cancer Center
San Francisco, California, United States, 94143
United States, Indiana
Indiana University Cancer Center
Indianapolis, Indiana, United States, 46202-5289
United States, Massachusetts
Children's Hospital Boston
Boston, Massachusetts, United States, 02115
United States, Ohio
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229-3039
United States, Pennsylvania
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
United States, Wisconsin
University of Wisconsin Comprehensive Cancer Center
Madison, Wisconsin, United States, 53792-6164
Sponsors and Collaborators
Children's Hospital Los Angeles
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: Katherine K. Matthay, MD University of California, San Francisco
Principal Investigator: Gregory Yanik, MD University of Michigan Rogel Cancer Center
Principal Investigator: John M. Maris, MD Children's Hospital of Philadelphia
Publications of Results:
Layout table for additonal information
Responsible Party: Katherine K. Matthay, M.D., UCSF School of Medicine Identifier: NCT00083135    
Other Study ID Numbers: CDR0000363631
P01CA081403 ( U.S. NIH Grant/Contract )
N2000-01 ( Other Identifier: NANT Consortium )
First Posted: May 17, 2004    Key Record Dates
Last Update Posted: October 15, 2010
Last Verified: May 2009
Keywords provided by Children's Hospital Los Angeles:
recurrent neuroblastoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroectodermal Tumors, Primitive, Peripheral
Neuroectodermal Tumors, Primitive
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action